Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCK1 | P35558 | 17/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976954 | 0.93 | PCK1 (1.00) | PCK1 | |
| Hydrochloric Acid SCHEMBL4613300 | 0.93 | PCK1 (0.98) | PCK1 | |
| SCHEMBL3980115 | 0.87 | PCK1 (0.81) | PCK1 | |
| SCHEMBL4092479 | 0.87 | PCK1 (1.00) | PCK1 | |
| Trifluoroacetic Acid SCHEMBL4614421 | 0.87 | PCK1 (0.88) | PCK1 | |
| Hydrochloric Acid SCHEMBL4613296 | 0.86 | PCK1 (0.80) | PCK1 | |
| Trifluoroacetic Acid SCHEMBL3981359 | 0.85 | PCK1 (0.74) | PCK1 | |
| SCHEMBL3976935 | 0.85 | PCK1 (0.86) | PCK1 | |
| SCHEMBL3986604 | 0.84 | PCK1 (0.83) | PCK1 | |
| SCHEMBL3976945 | 0.84 | PCK1 (1.00) | PCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | claimed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | claimed |
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | disclosed |
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1599477-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | disclosed |
| WO-2004074288-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | GYS2, SLC5A1, SLC5A2 | PCK1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.